Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Gomes, Douglas S ^a   Porto, Simone S ^a   Rocha, Rafael M ^b   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Breast cancer; Ductal carcinoma in situ; E cadherin; Immunohistochemistry; Lobular neoplasia; catenin

Indexed keywords

BETA CATENIN; CADHERIN; CDH1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST TUMOR; CARCINOMA IN SITU; CHEMISTRY; CLASSIFICATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG CARCINOMA; MIDDLE AGED; MIXED TUMOR; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASMS, COMPLEX AND MIXED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84880023637     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-114     Document Type: Article

References (24)

1. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. World Health Organization WHO classification of tumours of the breast 2012, Lyon: IARC, 4, World Health Organization.
2. Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H, Gown AM. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 2001, 115:534-542. 10.1309/B0DD-4M7H-GJG1-7KCW, 11293901.
3. Jacobs TW, Pliss N, Kouria G, Schnitt SJ. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001, 25:229-236. 10.1097/00000478-200102000-00011, 11176072.
4. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388. 10.1093/jnci/90.18.1371, 9747868.
5. Schnitt SJ, Morrow M. Lobular carcinoma in situ: current concepts and controversies. Semin Diagn Pathol 1999, 16:209-223.
6. Lakhani SR, Audretsch W, Cleton-Jensen AM, Cutuli B, Ellis I, Eusebi V, Greco M, Houslton RS, Kuhl CK, Kurtz J, et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. Eur J Cancer 2006, 42:2205-2211. 10.1016/j.ejca.2006.03.019, 16876991.
7. Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am 2000, 38:791-807. 10.1016/S0033-8389(05)70201-3, 10943278.
8. Nagi CS, O'Donnell JE, Tismenetsky M, Bleiweiss IJ, Jaffer SM. Lobular neoplasia on core needle biopsy does not require excision. Cancer 2008, 112:2152-2158. 10.1002/cncr.23415, 18348299.
9. Bratthauer GL, Moinfar F, Stamatakos MD, Mezzetti TP, Shekitka KM, Man YG, Tavassoli FA. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum Pathol 2002, 33:620-627. 10.1053/hupa.2002.124789, 12152161.
10. Choi YJ, Pinto MM, Hao L, Riba AK. Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. Mod Pathol 2008, 21:1224-1237. 10.1038/modpathol.2008.106, 18587329.
11. Gomes DS, Balabram D, Porto SS, Gobbi H. Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol 2011, 6:74. 10.1186/1746-1596-6-74, 3170574, 21827679.
12. Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, Clarke C, Lakhani SR, Simpson PT. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008, 32:773-783. 10.1097/PAS.0b013e318158d6c5, 18379416.
13. Goldstein NS, Kestin LL, Vicini FA. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001, 92:738-747. 10.1002/1097-0142(20010815)92:4<738::AID-CNCR1377>3.0.CO;2-Z, 11550142.
14. Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun 2009, 384:6-11. 10.1016/j.bbrc.2009.04.051, 2700729, 19379710.
15. Andrews JL, Kim AC, Hens JR. The role and function of cadherins in the mammary gland. Breast cancer res 2012, 14:203. 3496113, 22315958.
16. Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol 2013, 8:10. 10.1186/1746-1596-8-10, 3599130, 23337059.
17. Cheng H, Liang H, Qin Y, Liu Y. Nuclear beta-catenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer. Diagn Pathol 2011, 6:109. 10.1186/1746-1596-6-109, 3222611, 22053859.
18. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 2008, 28:3815-3826.
19. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001, 115:85-98. 10.1309/FDHX-L92R-BATQ-2GE0, 11190811.
20. Maluf HM, Swanson PE, Koerner FC. Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am J Surg Pathol 2001, 25:237-244. 10.1097/00000478-200102000-00012, 11176073.
21. Page DL, Anderson TJ. Diagnostic histopathology of the breast 1987, Edinburgh; New York: Churchill Livingstone.
22. Rosen PP. Rosen's breast pathology 2008, Philadelphia: Lippincott Williams & Wilkins, 3, 3686541, 23853574.
23. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol 2007, 31:427-437. 10.1097/01.pas.0000213386.63160.3f, 17325485.
24. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A, Cano A, Martin-Perez J, Gamallo C, Palacios J. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004, 23:3272-3283. 10.1038/sj.onc.1207439, 15077190.